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Received April 20, 2014; accepted November 10, 2014AbstractBackground: Transcatheter aortic valve implantation (TAVI) has emerged as an alternative to surgical aortic valve replacement for patients with
symptomatic severe aortic stenosis (AS) who have a high surgical risk. In Taiwan, this is the first study reporting TAVI outcomes at a single
center offering two different transcatheter heart valve technologies via four types of approaches. Our aim was to compare 30-day and 6-month
Valve Academic Research Consortium-2 (VARC-2) outcomes of the two valves.
Methods: We reported the procedural, 30-day, and 6-month VARC-2 outcomes of high-risk patients who were consecutively treated with the
Medtronic CoreValve (MCV) or with the Edwards SAPIEN valve or SAPIEN XT valve (ESV; Edwards Lifesciences, Irvine, CA, USA)
delivered via four types of approaches.
Results: From May 2010 to December 2013, 30 consecutive patients with severe AS underwent TAVI: 15 patients were treated with the MCVand
15 patients were treated with the ESV. The transfemoral approach was the most frequently used route (13 MCV and 6 ESV), followed by the
transapical approach (9 ESV), trans-subclavian approach (1 MCV), and direct aortic approach (1 MCV). There were no procedural deaths.
“Device success” was achieved in 29 (96.7%) patients, and is defined as the absence of procedural mortality, correct positioning of one prosthetic
heart valve into the proper anatomical location, and intended performance of the heart valve without moderate or severe regurgitation. The
VARC-2edefined combined safety endpoint at 30 days was comparable between patients treated with the ESV and the MCV (33.3% vs. 20%,
respectively; group, p ¼ 0.409). At the 6-month follow up, the combined efficacy endpoint was not significantly different between the two
groups (13.3% in the ESV group vs. 20% in the MCV group; p ¼ 0.624). There was only one (3.3%) patient who required permanent pacemaker
implantation.
Conclusion: For the first time in Taiwan, we have demonstrated that TAVI using either device is complementary and feasible for treating a wide
range of patients by using a careful selection of approaches. Favorable overall procedural success rates and 30-day and 6-month outcomes were
achieved with both devices.
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Degenerative aortic stenosis (AS) is the most common
valvular heart disease in adults. Its prevalence is approxi-
mately 4% in patients older than 80 years. After the onset of
symptoms (e.g., angina, syncope, or heart failure), the average
survival time is 2e3 years with a high risk of sudden death.1
Surgical aortic valve replacement (AVR), which has been the
only effective treatment in adults with severe symptomatic AS,
provides symptomatic relief and long-term survival.2 Howev-
er, in clinical practice, > 30% of patients with severe symp-
tomatic AS do not undergo AVR because of advanced age, left
ventricular dysfunction, or the presence of multiple coexisting
conditions.3e6
Transcatheter aortic valve implantation (TAVI) is a new
procedure in which a bioprosthetic valve is inserted through a
catheter and implanted within the diseased native aortic valve.
In 2002, the procedure was first performed.7 Since then, this
technology has evolved tremendously and has become an
established therapy in the treatment of symptomatic severe AS
in patients deemed at too high a risk for surgical AVR.8e15
Two devices have been in widespread use: the self-
expandable Medtronic CoreValve (MCV; Medtronic, Minne-
apolis, MN, USA) and balloon-expandable Edwards SAPIEN
or SAPIEN XT valve (ESV; Edwards Lifesciences, Irvine, CA,
USA). The MCV is a nitinol self-expandable porcine pericar-
dial tissue valve. The ESV was initially composed of stainless
steel (SAPIEN), but now composed of a cobalt chromium
frame (SAPIEN XT) with bovine pericardial leaflets. Both
valves reportedly have excellent flow characteristics, but each
has specific features and aortic anatomic requirements.
In Taiwan, our multidisciplinary team was the first to apply
to the Department of Health (DOH; Taipei, Taiwan) for
approval of the TAVI program using the Edwards SAPIEN
valve. In January 2010, the TAVI program was approved by
the DOH. Ten patients with symptomatic severe AS, who were
evaluated by surgeons as having a high surgical risk, under-
went TAVI in our hospital.16,17 In December 2013, the Min-
istry of Health and Welfare (Taipei, Taiwan) granted approval
of the MCV. Since then, the MCV has been predominantly
used in our center, except for patients who did not meet the
anatomical criteria required for MCV implantation. Trans-
catheter aortic valve implantation was performed with the
Edwards SAPIEN XT device for patients who were unsuitable
for MCV.
To date, our institution offers two different transcatheter
heart valve technologies in Taiwan. The aim of this single-
center study was to compare 30-day and 6-month Valve Ac-
ademic Research Consortium-2 (VARC-2)18 outcomes after
TAVI with ESV versus with MCV.
2. Methods2.1. PatientsFrom May 2010 to December 2013 at our center, 30
consecutive patients underwent TAVI who had severe AS (i.e.,valve area  1.0 cm2 and mean aortic valve gradient
 40 mmHg). All patients had New York Heart Association
(NYHA) symptoms greater than Class II. Patients were selected
for TAVI when they were considered unsuitable or at high risk
for surgical AVR by the heart team discussion. Operative risk
was calculated using the logistic European System for Cardiac
Operative Risk Evaluation (EuroSCORE) score and the Society
of Thoracic Surgeons predictive risk for mortality score.
Patients at high surgical risk had a logistic EuroSCORE 20%;
significant comorbidities; or other risk factors such as a por-
celain aorta, previous chest radiation, the presence of patent
coronary artery bypass grafts, liver cirrhosis, and frailty. Pa-
tients for whom TAVI was deemed as the best treatment option
were selected based on the clinical consensus of a multidisci-
plinary team consisting of cardiac surgeons, interventional
cardiologists, anesthetists, and imaging specialists.
The main exclusion criteria were a native aortic valve
annulus of < 18 mm or > 29 mm, an acute myocardial
infarction of < 14 days, a left ventricular ejection fraction of
< 20%, active infection, hemodynamic instability, or a life
expectancy of < 12 months.2.2. DevicesIn our practice, we initially performed TAVI with the
Edwards SAPIEN valve (in 10 patients) in 2010. We then
added the MCV to our practice after it was approved in
December 2013. The MCV system has been predominantly
used since then in our center. For patients unsuitable for MCV
implantation (such as patients with shallow coronary sinuses
or a dilated ascending aorta), TAVI was performed with the
Edwards SAPIEN XT device.2.3. MCV suitabilityThe annular dimension requirements for MCV are
20e23 mm for the 26-mm device, 23e27 mm for the 29-mm
device, and 26e29 mm for the 31-mm device.9 For trans-
femoral access, the device requires an 18-F delivery system
and thus a minimal iliofemoral dimension of at least 6 mm.
Adequate sinus of Valsalva width (> 27 mm for the 26-mm
valve, and > 29 mm for the 29-mm and 31-mm valves) is
also required. The ascending aortic diameter 40 mm distal to
the aortic annulus should be < 40 mm for the 26-mm valve
and < 43 mm for the 29-mm and 31-mm valves.2.4. Edwards suitabilityThe annular dimension criteria for the Edwards SAPIEN
device or SAPIEN XT device is 18e21 mm for the 23-mm
device, 22e25 mm for the 26-mm device, and 25e27 mm
for the 29-mm device.19 The transfemoral access requirements
for the Edwards SAPIEN valve with the RetroFlex 3 System
(Edwards Lifesciences) is a minimal iliofemoral dimension of
7 mm for the 22-F/23-mm device, and a minimal iliofemoral
dimension of 8 mm for the 24-F/26-mm device. The next-
generation Edwards system (Edwards SAPIEN XT, USA)
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introduces the Edwards expandable sheath (i.e., e-sheath),
available in sizes of 16-F and 18-F for the 23-mm and 26-mm
devices, respectively. The criteria for feasibility include a
minimal iliofemoral dimension of 6 mm for the 23-mm valve
and a minimal iliofemoral dimension of 6.5 mm for the
26-mm valve.2.5. ProceduresDepending on the patient's clinical conditions and the an-
esthesiologist's evaluation of the patient, the procedure was
performed under general anesthesia or under local anesthesia
with conscious sedation. The transapical procedures were all
performed under general anesthesia. The standard approach
for both valves was through the transfemoral route, if feasible.
In patients who did not have the adequate anatomy to allow a
safe transfemoral access, alternative access routes were used
such as the transapical access20 for the ESV, and the trans-
subclavian access21 or direct aortic access22 for the MCV.
Adjunctive pharmacologic therapy included administering
heparin during the procedure, aspirin (100 mg/d) indefinitely,
and clopidogrel (75 mg/d) for 3e6 months after the procedure.
2.5.1. Transfemoral approach
Transfemoral procedures were performed by the surgical
cutdown of the femoral arteries or by the double-ProGlide
(Abbott Vascular, Redwood, CA, USA) preclose technique.23
After retrograde predilation of the native valve, the valve
was crossed and implanted, as previously described.8
2.5.2. Transapical approach
For the transapical procedure, a left anterolateral mini-
thoracotomy and pericardiotomy were performed. A double-
pledgeted purse-string suture or U stitches were placed at the
left ventricular apex. After puncturing the apex and performing
antegrade crossing and predilation, the ESV was deployed
under rapid ventricular pacing, as previously reported.20
2.5.3. Trans-subclavian approach
This procedure required surgical isolation of the left axil-
lary artery. Once the artery was isolated, a purse-string suture
was placed to allow subsequent closure at the end of the
procedure. The artery was punctured at the distal end of the
purse string, and a 6-F sheath was placed into the artery. A
standard 0.035-inch guide wire was then exchanged for a
preshaped 0.035-inch Amplatz Super Stiff guide wire (Boston
Scientific, Marlborough, MA, USA), and an 18-F sheath was
positioned in the axillary artery. The valve was crossed with
the same procedure previously described for the transfemoral
approach.8 The axillary access site was then surgically
repaired.21
2.5.4. Direct aortic approach
The procedure was performed through a 5-cm incision in the
right second intercostal space. A right anterior mini-
thoracotomy was formed so that the medial angle of incisionwas positioned just before the projection of the right internal
mammary artery 1.5e2 cm lateral to the sternal edge. Basal
ascending aorta aortography, using a graduated pigtail, was
performed to measure the distance between the aortic annulus
and the selected entry site in the ascending aorta. More than
6 cm were needed to safely perform MCV implantation. At the
entry site, two aortic purse-string sutures for direct aortic access
were placed in a standard fashion, as previously reported.222.6. Study endpointsAll clinical endpoints of this study were defined according
to the VARC-2 criteria.18 “Device success” was defined as the
absence of procedural mortality, correct positioning of a single
prosthetic heart valve into the proper anatomical location, and
intended performance of the prosthetic heart valve (i.e., no
prosthesisepatient mismatch and a mean aortic valve
gradient < 20 mmHg or peak velocity > 3 m/s, and no mod-
erate or severe prosthetic valve regurgitation). After valve
deployment, independent investigators assessed the patient's
valve function using transthoracic echocardiography prior to
discharge, at the 3-month follow up, and at the 6-month follow
up. The 30-day-combined safety endpoint is a combined
endpoint, defined by VARC-2 as a composite of all-cause
mortality, major stroke, life-threatening or disabling
bleeding, acute stage 2 or 3 kidney injury such as renal
replacement therapy, major vascular complications, and a
repeat procedure for valve-related dysfunction. The VARC-2
proposed using the Acute Kidney Injury Network (AKIN)
system for reporting acute kidney injury (AKI). “Acute kidney
injury” was defined as an absolute (i.e., < 48 hours) reduction
in kidney function and classified as stage 1 for a 150e199%
increase in the serum creatinine level (i.e., 1.5e1.99  the
amount of increase from the baseline), or an increase in the
creatinine level of > 0.3 mg/dL, or a urine output of < 0.5 mL/
kg/h for > 6 hours but < 12 hours; as stage 2 for a 200e299%
increase in the serum creatinine level (i.e., 2.0e2.9  the
amount of increase from the baseline level) or a urine output
of < 0.5 mL/kg/h for > 12 hours but < 24 hours; and as stage 3
for an increase in serum creatinine level of > 300% (i.e., >
3  the amount of increase from the baseline level) or a serum
creatinine level of > 4.0 mg/dL with an acute increase of at
least 0.5 mg/dL, or a new need for renal replacement therapy
post-TAVI. The combined efficacy endpoint was defined as a
composite of all-cause mortality, stroke, requirement of hos-
pitalization for worsening heart failure, and valve-related
dysfunction.2.7. Statistical analysisContinuous variables were expressed as the mean ± the
standard deviation, and were analyzed with the Student t test
or Wilcoxon rank sum test, depending on the variable distri-
bution. Categorical variables were compared with the Chi-
square test using Yates' correction for continuity or the
Fisher's exact test. For all comparisons, p < 0.05 was
considered statistically significant.
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patients undergoing TAVI in our center were included in this
analysis. The mean age was 81.3 ± 5.2 years, and all patients
had severe symptomatic AS (i.e., mean aortic valve area,
0.61 cm2; mean transaortic gradient, 50.1 ± 2.4 mmHg).
Among these patients, two (6.7%) patients had a bicuspid
aortic valve and two (6.7%) patients had previously undergone
mitral valve replacement with a mechanical prosthesis. Table 1
shows the baseline clinical and echocardiographic character-
istics of the study population. No significant differences were
observed with respect to sex, body surface area, logistic
EuroSCORE, NYHA class, aortic valve area, and mean pres-
sure gradient between patients treated with ESV and patients
treated with MCV. Compared to patients receiving the MCV,
patients in the ESV group had a significantly lower baselineTable 1
Baseline characteristics of the study population (n ¼ 30).
Variable Overall
(n ¼ 30)
ESV
(n ¼ 15)
MCV
(n ¼ 15)
p
Age (y) 81.3 ± 5.2 81.9 ± 2.6 80.7 ± 7.0 0.542
Men 14 (46.7) 7 (46.7) 7 (46.7) > 0.99
Body mass index (kg/m2) 23.0 ± 2.7 23.6 ± 2.9 22.5 ± 2.4 0.274
Body surface area (m2) 1.56 ± 0.17 1.57 ± 0.15 1.55 ± 0.19 0.737
Hypertension 25 (83.3) 11 (73.3) 14 (93.3) 0.142
Diabetes mellitus 11 (36.7) 6 (40) 5 (33.3) 0.705
Hyperlipidemia 14 (46.7) 8 (53.3) 6 (40) 0.464
NYHA class III or IV 30 (100) 15 (100) 15 (100) > 0.99
CAD 11 (36.7) 4 (26.7) 7 (46.7) 0.256
Previous MI 1 (3.3) 1 (6.7) 0 0.309
Previous PCI 10 (33.3) 4 (26.7) 6 (40) 0.439
Previous CABG 2 (6.7) 0 2 (13.3) 0.143
Peripheral artery disease 4 (13.3) 2 (13.3) 2 (13.3) > 0.99
Cerebrovascular disease 7 (23.3) 4 (26.7) 3 (20) 0.666
Pulmonary disease 16 (53.3) 8 (53.3) 8 (53.3) > 0.99
Previous BAV 8 (26.7) 3 (20) 5 (33.3) 0.409
Previous pacemaker 0 0 0 > 0.99
Logistic EuroSCORE (%) 25.1 ± 11.2 25.8 ± 11.8 24.4 ± 10.9 0.742
Serum creatinine (mg/dL) 1.1 ± 0.5 1.3 ± 0.6 1.0 ± 0.3 0.055
Estimated GFR (mL/min) 54.8 ± 25.8 40.4 ± 16.3 69.3 ± 25.8 0.001
Estimated GFR
(<60 mL/min)
17 (56.7) 13 (86.7) 4 (26.7) 0.001
Bicuspid valve 2 (6.7) 2 (13.3) 0 0.143
Previous mitral prosthesis 2 (6.7) 1 (6.7) 1 (6.7) > 0.99
Neoplasm 3 (10) 1 (6.7) 2 (13.3) 0.543
Echocardiographic findings
Aortic valve area (cm2) 0.61 ± 0.17 0.58 ± 0.18 0.64 ± 0.17 0.377
Mean PG (mmHg) 50.1 ± 20.4 49.6 ± 16.8 50.7 ± 24.1 0.881
LVEF (%) 55.1 ± 8.7 59.4 ± 8.0 50.9 ± 7.4 0.006
sPAP (>60 mmHg) 4 (13.3) 1 (6.7) 3 (20) 0.283
Data are presented as n (%) or mean ± the standard deviation.
BAV ¼ balloon aortic valvuloplasty; CABG ¼ coronary artery bypass graft-
ing; CAD ¼ coronary artery disease; ESV ¼ Edwards SAPIEN or SAPIEN
XT valve; GFR ¼ glomerular filtration rate; Logistic EuroSCORE ¼ Logistic
European System for Cardiac Operative Risk Evaluation; LVEF ¼ left ven-
tricular ejection fraction; MCV ¼ Medtronic CoreValve; MI ¼ myocardial
infarction; NYHA¼New York Heart Association; PCI ¼ percutaneous cor-
onary intervention; PG ¼ pressure gradient; sPAP ¼ systolic pulmonary
arterial pressure.estimated glomerular filtration rate [GFR; 40.4 ± 16.3 mL/min
(ESV) vs. 69.3 ± 25.8 mL/min (MCR); p ¼ 0.001] and higher
left ventricular ejection fraction (59.4 ± 8.0% vs. 50.9 ± 7.4%,
respectively; p ¼ 0.006).3.2. Procedural outcomesTable 2 presents the main procedural variables. The trans-
femoral approach was the most frequently used route (63.3%),
followed by the transapical approach (30%). The ESV device
was implanted in 15 patients [in 6 (40%) patients via the
transfemoral approach and in 9 (60%) patients via the trans-
apical approach]. TheMCV devicewas implanted in 15 patients
[in 13 (86.7%) patients via the transfemoral approach, in 1
(6.7%) patient via the trans-subclavian approach, and in 1
(6.7%) patient via the direct aortic approach]. The transfemoral
approach was less frequently used for the implantation of the
ESV than for the MCV (40% vs. 86.7%, respectively;
p ¼ 0.004). Transcatheter aortic valve implantation was per-
formed using local anesthesia in two (6.7%) patients in theMCV
group. No significant difference was observed in the amount of
contrast medium administered (212± 102mL in the ESV group
vs. 178 ± 84 mL in the MCV group; p ¼ 0.360). The mostTable 2
The procedural characteristics and postprocedural outcomes of the study
population (n ¼ 30) at < 72 hours after the index procedure.
Variable Overall
(n ¼ 30)
ESV
(n ¼ 15)
MCV
(n ¼ 15)
p
Bioprosthesis size
ESV (23 mm) 6 (40)
ESV (26 mm) 8 (53.3)
ESV (29 mm) 1 (6.7)
MCV (26 mm) 6 (40)
MCV (29 mm) 9 (60)
Access 0.004
Transfemoral 19 (63.3) 6 (40) 13 (86.7)
Transapical 9 (30) 9 (60) 0
Trans-subclavian 1 (3.3) 0 1 (6.7)
Direct aortic 1 (3.3) 0 1 (6.7%)
Contrast volume (mL) 192 ± 91 212 ± 102 178 ± 84 0.360
Local anesthesia 2 (6.7) 0 2 (13.3) 0.143
Device success a 29 (96.7) 14 (93.3) 15 (100) 0.309
Myocardial infarction 1 (3.3) 1 (6.7) 0 0.309
Stroke or TIA 1 (3.3) 0 1 (6.7) b 0.309
Acute kidney injury, stage 2 or 3 3 (10) 2 (13.3) 1 (6.7) 0.543
Major vascular complications 1 (3.3) 0 1 (6.7) b 0.309
New pacemaker implantation 1 (3.3) 1 (6.7) 0 0.309
Coronary obstruction 0 0 0 > 0.99
Cardiac tamponade 2 (6.7) 1 (6.7) 1 (6.7) b > 0.99
Annulus rupture 0 0 0 > 0.99
Valve malpositioning 0 0 0 > 0.99
Need for a second valve 0 0 0 > 0.99
Posptocedural AR grade >2 1 (3.3) 1 (6.7) 0 0.309
Data are presented as n (%) or mean ± the standard deviation.
AR ¼ aortic regurgitation; ESV ¼ Edwards SAPEIN/SAPEIN XT valve;
MCV ¼ Medtronic CoreValve; TIA ¼ transient ischemic attack.
a
“Device success” is defined as the absence of procedural mortality, correct
positioning of a single prosthetic heart valve into the proper anatomical
location, and intended performance of the heart valve without moderate or
severe regurgitation.
b All events occurred in one patient.
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ESV group and the 29-mm valve (60%) in the MCV group.
Table 2 summarizes the procedural outcomes. Device success
was achieved in 29 (96.7%) patients. One (3.3%) patient with
bicuspid aortic valve and horizontal aorta in the ESV group had
postproceduralmoderate paravalvular regurgitation, as assessed
by angiography and echocardiography. No procedural death
occurred within the first 72 hours after TAVI. In the ESV group,
one (3.3%) patient had periprocedural myocardial infarction.
Acute kidney injury requiring temporary dialysis occurred in
three (10%) patients: two patients in the ESV group and one
MCV recipient. Two (6.7%) patients had cardiac tamponade
(categorized as life-threatening bleeding, according to the
VARC-2 definition). In the first patient, cardiac tamponade
occurred immediately after the deployment of the 26-mm
Edwards SAPIEN valve, and prompt pericardiocentesis suc-
cessfully stabilized the patient. It may have resulted from an
aortic tear caused by asymmetrical distribution of aortic annulus
calcification. The second patient had a left ventricular perfora-
tion (defined as a major vascular complication by the VARC-2)
caused by the Amplatz Superstiff wire soon after the implan-
tation of a 29-mm CoreValve. Pericardiocentesis was insuffi-
cient; therefore, surgical closure was performed. This patient
developed a stroke from hypovolemic shock. Only one (3.3%)
patient with bicuspid aortic valve required a permanent pace-
maker after the implantation of a 29-mm Edwards SAPIEN XT
valve. Proper device positioning was achieved in all patients,
and no patient needed a second valve.3.3. The VARC-2 outcome at 30 days and 6 monthsTable 3 summarizes the 30-day and 6-month outcomes. At
the 30-day follow up, no cardiovascular death had occurred.Table 3
The VARC-2 outcomes at the 30-day and 6-month follow up.
Outcome
30 days
All-cause mortality
Cardiac mortality
All stroke
Life-threatening bleeding
Acute kidney injury, stage 2 or 3
Coronary artery obstruction
Major vascular complication
Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)
Combined safety end point
6-month cumulative clinical outcomes
All-cause mortality
Cardiac mortality
All stroke
Requiring hospitalizations for worsening heart failure
NYHA class III or IV
Valve-related dysfunction a
Combined efficacy
Data are presented as n (%) or mean ± the standard deviation.
BAV ¼ balloon aortic valvuloplasty; ESV ¼ Edwards SAPIEN or SAPIEN XT v
SAVR ¼ surgical aortic valve replacement; TAVI ¼ transcatheter aortic valve imp
a
“Valve-related dysfunction” refers to a mean aortic valve gradient > 20 mmHg
0.35 m/s, and/or moderate or severe prosthetic valve regurgitation.One patient in the ESV group died 25 days after the trans-
apical procedure because of pneumonia and subsequent sepsis.
Stage 3 AKI developed in two (6.7%) patients after 72 hours:
one patient in the ESV group and one patient in the MCV
group. The cumulative incidence of stage 2 or 3 AKI at the 30-
day follow up was 16.7% (5 patients); of these patients, three
(10%) patients had to be dialyzed temporarily and one (3.3%)
patient needed chronic renal replacement therapy. Patients
who presented with AKI had a significantly lower baseline
estimated GFR, compared to patients not experiencing post-
procedural renal impairment (26.0 ± 10.8 mL/min vs.
60.6 ± 24.0 mL/min, respectively; p ¼ 0.003) and a higher
serum creatinine level (1.94 ± 0.71 mg/dL vs. 0.97 ± 0.29 mg/
dL, respectively; p ¼ 0.035). They also more frequently had a
history of coronary artery disease (80% vs. 28%, respectively;
p ¼ 0.033) and tended to have a higher logistic EuroSCORE
score (34.1 ± 10.0% vs. 23.3 ± 10.7%, respectively;
p ¼ 0.053). There was no association between AKI and hy-
pertension, diabetes, echocardiographic parameters, or
contrast medium volume. There was no coronary artery
obstruction or valve-related dysfunction requiring a repeat
procedure within 30 days. The VASC-2edefined combined
safety endpoints at 30 days were consequently comparable
between patients treated with ESVor with MCV (33.3% in the
ESV group vs. 20% in the MCV group; p ¼ 0.409).
Between 30 days and 6 months, three more patients died
(1 patient in the ESV group and 2 patients in the MCV group),
which resulted in a 6-month cumulative all-cause mortality
rate of 13.3%. No death was cardiac-related. One patient in the
ESV group who required chronic renal replacement therapy
died at 147 days because of an intracranial hemorrhage after a
fall. Another two patients in the MCV group died between 30
days and 6 months. Both developed AKI after the TAVI; oneOverall (n ¼ 30) ESV (n ¼ 15) MCV (n ¼ 15) p
1 (3.3) 1 (6.7) 0 0.309
0 0 0 > 0.99
1 (3.3) 0 1 (6.7) 0.309
2 (6.7) 1 (6.7) 1 (6.7) > 0.99
5 (16.7) 3 (20) 2 (13.3) 0.624
0 0 0 > 0.99
1 (3.3) 0 1 (6.7) 0.309
0 0 0 > 0.99
8 (26.7) 5 (33.3) 3 (20) 0.409
4 (13.3) 2 (13.3) 2 (13.3) > 0.99
0 0 0 > 0.99
1 (3.3) 0 1 (6.7) 0.309
1 (3.3) 0 1 (6.7) 0.309
1 (3.3) 0 1 (6.7) 0.309
0 0 0 > 0.99
5 (16.7) 2 (13.3) 3 (20) 0.624
alve; MCV ¼ Medtronic CoreValve; NYHA¼New York Heart Association;
lantation; VARC¼Valve Academic Research Consortium.
, an effective orifice area <0.9e1.1 cm2, and/or a Doppler velocity index of <
336 H.-H. Chang et al. / Journal of the Chinese Medical Association 78 (2015) 331e338patient needed rehospitalization for heart failure (NYHA Class
IV) at 57 days and died of recurrent infection and multiorgan
failure from sepsis at 98 days, and the other patient had
repeated upper gastrointestinal bleeding and recurrent infec-
tion and died of sepsis at 179 days.
No valve-related dysfunction, which includes the presence
of moderate or severe prosthesis regurgitation, was observed
within 6 months. The VASC-2-defined combined efficacy
endpoints at the 6-month follow up was accordingly the same
in both groups (13.3%). At 6 months, the patients who expe-
rienced AKI had a higher all-cause mortality, compared to
patients without AKI (60% vs. 3.6%, respectively), which
remained statistically significant in the age and sex-adjusted
Cox regression model (hazard ratio, 14.2; p ¼ 0.026).
4. Discussion
In Taiwan, this is the first study reporting TAVI outcomes at
a single center that offers two different transcatheter heart
valve technologies via four different approaches in high-risk
patients with severe AS. The overall device success rate of
96.7% is encouraging, and suggests that, with careful planning
and appropriate technique, immediate procedural success can
be achieved in most patients in whom the procedure is
attempted.
Transcatheter aortic valve implantation has been very suc-
cessfully used in the treatment of high-risk and inoperable
patients with severe AS. The two devices in mainstream use
are the MCV and the ESV. In December 2013, the Ministry of
Health and Welfare (Taipei, Taiwan) granted approval of the
self-expandable MCV. Since then, the device has been pre-
dominantly used in Taiwan. However, three (16.7%) of our 18
patients assessed by the Medtronic core lab were ineligible for
treatment with the MCV system: two patients had shallow
coronary sinuses and one patient had a severely angulated and
dilated ascending aorta. Therefore, the use of either device is
complementary and makes TAVI feasible for patients with a
wide array of anatomic dimensions. In addition, using various
access routes ensures that most patients can be treated.
In our cohort, the transfemoral approach was less
frequently used for implanting the ESV than for implanting
the MCV (40% vs. 86.7%, respectively; p ¼ 0.004). Two-
thirds of the ESVs were implanted in 2010, when only the
earlier generation RetroFlex System (which requires the use of
the larger diameter 22-F to 24-F sheath) was available;
therefore, a comparison of the ESVs, which were mostly
implanted via transapical approach, and the MCVs, which
were mostly implanted via transfemoral approach, is unfair, to
some extent. Alli et al24 report that there was consistently a
learning curve for TAVI and that at least 30 procedures were
needed for procedural proficiency. We still achieved excellent
results, despite being in the learning curve period.
Accumulating data have linked device failure and more-
than-mild aortic regurgitation (AR) after TAVI with signifi-
cantly increased long-term mortality after TAVI.13,25 No pa-
tient in our series had valve embolization, ectopic valve
deployment, the need for a valve-in-valve procedure, orconversion to surgery. Higher frequencies of postprocedural
AR have been more recently reported for MCV than for ESV
in a well-balanced cohort from the United Kingdom Trans-
catheter Aortic Valve Implantation (U.K. TAVI) registry (452
MCV patients vs. 410 ESV patients; moderate AR vs. severe
AR, 17.3% vs. 9.6%, respectively; p ¼ 0.001)14 and in the
large French Transcatheter Aortic Valve Intervention Registry
(FRANCE-2) study [21.5% (MCV) vs. 13.9% (ESV)].15 By
contrast, in a recently published multicenter collaborative
studydthe Pooled-Rotterdam-Milano-Toulouse In Collabora-
tion Plus (PRAGMATIC PLUS) Initiativedthe incidence of
more-than-mild AR was extremely low and comparable be-
tween both devices (2.0% with MCV and 1.8% with ESV).26
In all of these studies, the AR was assessed by angiography
(U.K. registries) or by echocardiography (FRANCE 2 and
PRAGMATIC PLUS). In our institution, valve function after
TAVI was assessed by independent investigators using trans-
thoracic echocardiography prior to discharge, at the 3-month
follow up, and at the 6-month follow up. There was only
one (3.3%) patient with bicuspid aortic valve and horizontal
aorta in the ESV group who experienced postprocedural
moderate paravalvular regurgitation.
The MCV implantation is frequently associated with
atrioventricular block that requires pacemaker placement. This
is possibly because of greater expansion into the left ventric-
ular outflow tract with compression of the septal conduction
tissues. The need for permanent pacemaker placement after
MCV implantation has accordingly been reported in
25.8e33.0% of patients.27,28 In our study, the rate of perma-
nent pacemaker requirement was only 3.3% (one patient in the
ESV group with a bicuspid aortic valve received a 29-mm
device), which is one of the lowest rates that has been
observed so far.27,28 That may result from our high implan-
tation strategy for the MCV system at a target depth of 
6 mm below the annulus. The strategy has to be validated in
further studies to confirm whether it can abolish the high rate
of permanent pacemaker requirement with MCV implantation.
Our results are encouraging overall, but the incidence of
stage 3 AKI at 30 days was 16.7% (5 patients); of these, three
(10%) patients had to be dialyzed temporarily and one (3.3%)
patient needed chronic renal replacement therapy. The inci-
dence of AKI in large analyses was 20e21%, and severe
worsening of renal function (i.e., AKI stages 2 and 3) occurred
in 5.3% of patients.29,30 Transcatheter aortic valve
implantation-related AKI was associated with increased 30-
day, 6-month, and 1-year mortality.31,32 In our series, pa-
tients who developed AKI had significantly lower baseline
estimated GFR and higher serum creatinine level. No signifi-
cant differences existed in the amount of contrast media
administered. At 6 months, patients who experienced AKI had
a higher all-cause mortality, compared to patients without AKI
(60% vs. 3.3%, respectively; p ¼ 0.001), which remained
statistically significant in the age and sex-adjusted Cox
regression model (hazard ratio, 14.2; p ¼ 0.026).
The present study summarizes a rather small number of
high-risk patients and encompasses the experience of a single
center. Therefore, the generalizability of our findings may not
337H.-H. Chang et al. / Journal of the Chinese Medical Association 78 (2015) 331e338extend to all clinical centers performing TAVI. The present
study was prospective, but the choice of treatment was not
randomized. In addition, there may be a learning curve for the
procedure and with regard to careful patient selection because
of many risk factors and contraindications that are known to
date and are better understood with increasing experience. In
the present study, all patients were monitored by overseas
proctors. Thus, the study outcomes may not reflect real-world
scenarios. Further technical improvements of the technology
will definitely lead to the evolution of smaller devices, which
may rapidly increase the number of transfemoral procedures
performed.
In conclusion, our data demonstrated that TAVI is a safe
and effective procedure in selected extreme high-risk elderly
patients with severe AS. With the current state of the art
techniques, and various alternative approaches, TAVI can be
applied in a wide range of patients.
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